Uses of salvianolic acid A in preventing and/or treating diabetes and complication

A technology of diabetes and salvianolic acid, which is applied in the field of medicine and can solve the problems of no direct therapeutic effect reported

Active Publication Date: 2012-01-04
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Recent studies on the effects of Salvia miltiorrhiza mainly focus on improving the ischemia-reperfusion injury of heart, liver, lung, brain and other organs; damage to liver cells; liver fibrosis, liver cirrhosis, and liver cancer; regulation of immune response; In terms of preventing and tr...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of salvianolic acid A in preventing and/or treating diabetes and complication
  • Uses of salvianolic acid A in preventing and/or treating diabetes and complication
  • Uses of salvianolic acid A in preventing and/or treating diabetes and complication

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Example 1. Effect of salvianolic acid A on blood sugar in normal mice

[0069] Method: 50 mice were randomly divided into 5 groups, weighing 17-20g, fed with complete nutrition feed, without restriction of water. The normal control group was given equal volume of normal saline, the positive control group was given metformin 150 mg / kg, and the other three groups were given salvianolic acid A aqueous solution 10 mg / kg, 3 mg / kg, and 1 mg / kg respectively. Dosing for 6 consecutive days, on the 6th day (fasting for 14h), blood was taken once by docking the tail (20ul of blood was diluted with 20ul of normal saline, and the supernatant was taken), and then administered, and after 2h (fasting for 16h), the eyeball was picked to take blood, routine The serum was separated, and the blood glucose content of mice was determined according to the instructions of the blood glucose determination kit (hexokinase method, Zhongsheng Beikong Biotechnology Co., Ltd.).

[0070] Results: Bot...

Embodiment 2

[0072] Example 2. Effect of salvianolic acid A on blood sugar in diabetic rats

[0073] Method: SD rats were intraperitoneally injected with streptozotocin 30 mg / kg, and injected twice with an interval of one week, and then used a Roche blood glucose meter to measure blood sugar, and the blood sugar value was higher than 11.5 as diabetic rats for the experiment. Animal groups: normal group, model group, salvianolic acid A high-dose 5mg / kg group, low-dose 1mg / kg group. 7 in each group. Salvianolic acid A was injected intraperitoneally for 6 consecutive days. Feed a normal, complete nutritional diet during this period. After 5 days, measure the blood sugar level of the animals in the state of eating, fast for 8 hours on the 6th day, measure the basal blood sugar level as the zero-time blood sample, and then inject intraperitoneally, and then administer glucose 2g / kg (2ml) in each experimental group 60 minutes after the administration , and 30, 60, 120 min, 180 min after the g...

Embodiment 3

[0075] Example 3. Effect of salvianolic acid A on glucose absorption of human liver cancer cell line Bel-7401

[0076] Methods: Bel-7401 cells were routinely cultured in 10% FBS 1640. Trypsinization, 3 × 10 3 The cells / well were routinely planted in 96-well cell culture plates, and after 16 hours, when the cells were completely adhered to the wall, different concentrations of salvianolic acid A (final concentration 10 -5 M-10 -9 M) phenol red-free serum-free 1640 medium, insulin (final concentration 0.04U / ml) control group treated the same. After 72 hours, the glucose concentration in the supernatant was measured, and the cell content was detected by the SRB method. 72 hours after adding the drug, the glucose content in the supernatant was detected, and the amount of cells was detected by the SRB method. The result: salA10 -6 M-10 -8 M dose group can promote the absorption of glucose by human liver cancer cell line Bel-7401 cells, in which salA10 -6 The effect of promoti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a salvianolic acid A which can reduce blood sugar of animals, promote cellular glucose absorption, alleviate diabetic hyperglycemia, prevent and treat diabetic cardiovascular complications, diabetic nephrosis, diabetic peripheral circulatory disorder and diabetic peripheral nervous lesion, decrease blood lipid, reduce weight of mammals and improve generation of a cellular energy substance ATP so as to promote wound healing and metabolism function, thus the salvianolic acid A can be used for preventing and treating the diabetic hyperglycemia, the diabetic cardiovascular complications, the diabetic nephrosis, the diabetic peripheral nervous lesion, the peripheral circulatory disorder (angiopathy, diabetic gangrene and foot ulcer), obesity and hyperlipemia, can promote wound healing (various wounds, burn, scald, cutaneous erosion, decubitus as well as skin injury and mucosal injury caused by skin grafting and radiation).

Description

technical field [0001] The present invention relates to salvianolic acid A in the prevention and treatment of diabetic hyperglycemia, diabetic cardiovascular complications, diabetic nephropathy, diabetic peripheral neuropathy, peripheral circulatory disorder (vascular disease, diabetic gangrene, foot ulcer), obesity, hyperlipidemia , to promote wound healing (various wounds, burns, scalds, skin erosions, decubitus, skin grafting, radiation-induced skin and mucous membrane damage), and belongs to the field of medical technology. Background technique [0002] Diabetes is a group of metabolic diseases characterized by elevated blood glucose concentrations. The pathophysiological mechanisms that cause hyperglycemia are defects in insulin secretion and insulin action. Polyuria, polydipsia, and weight loss may occur when blood sugar is significantly increased, and sometimes it may be accompanied by polyphagia and blurred vision. Acute ketoacidosis and nonketotic hyperosmolar syn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61P3/04A61P25/02A61P13/12A61P17/02A61P9/00A61P3/06A61K31/216A61P3/10
Inventor 杜冠华杨秀颖王珂
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap